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Abstract
Background: Little is known about the aetiology of chronic lymphocytic leukaemia (CLL). The family medical history
is a ’’genomic tool’’ capturing interactions of genetic susceptibility, shared environment and common behaviours.
Methods: A cohort of 66 consecutives patients with CLL (probands) was studied in a medical oncology practice
(W.W.) from 1981 until 2005. A German version of the NCI medical history questionnaire for cancer aetiology
was used. Familial clustering analysis was done by comparing the proportion of specific tumours in the first degree
relatives of the CLL practice cohort with corresponding proportions of population-based cancer registry data.
Results: 18 (41%) male and 5 (23%) female CLL probands had multiple malignancies, e.g. 2 meningiomas, 
7 and 19 years after diagnosis of CLL. 46 (12%) first degree relatives had malignancies with an excess of CLL.
Other conspicuous familial associations are CLL with malignancies of the upper GI tract (oesophagus, stomach)
and of the nervous system.
Conclusions: 1. Chronic lymphocytic leukaemia clusters in some families like any other disease. Predisposition
genes should be searched. 2. Cancer prevention and early detection should be continued in CLL patients
because of their longevity and high risk for multiple malignancies. 3. The overrepresentation of upper GI
malignancies in first degree relatives of CLL patients calls for targeted oesophago-gastroscopy screening studies. 
Introduction
Every human disease clusters in families to some
extent. This is also true for cancer. All sites show an
excess of cancers of the same site among relatives, with
thyroid and colon cancers and lymphocytic leukaemia
showing the highest familial risks [1]. There is also
familial clustering of malignancies originating from
different primary sites [2].
Taking the family history of cancer patients is a low
technology approach which can be applied all over
the world [3]. It is a tool to identify high risk persons
and families and to down-stage disease by targeted
prevention and therapeutic approaches [4].
The family medical history represents a ’’genomic
tool’’ that can capture interactions of genetic
susceptibility, shared environment, and common
behaviours in relation to disease risk [5]. It is well suited
to research into cancer aetiology, of which little is
known in chronic lymphocytic leukaemia (CLL), the
most common form of leukaemia [6].
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Table 1. Multiple primaries in 23 patients with CLL










Skin (melanoma, CLL 2
sweat gland)
Skin (basalioma) CLL oesophagus 1








CLL essential anus 1
thrombocythaemia
OMF CLL 1
Table 2. Malignancies in 46 first degree relatives
Cancer site Male Female Total
Uncertain 3 3 6*
CLL 2 3 5*
Breast 0 4 4
Stomach 2 2 4
Oesophagus 3 0 3*
Colorectum 3 0 3
Lung 3 0 3
Brain 3 0 3*
Leukaemia 0 3 3*
Skin 0 2 2
ENT 1 0 1
Liver 1 0 1
C. tissue 1 0 1




Thyroid 1 0 1
NHL 1 0 1
Myeloma 1 0 1
Other 0 0 0
Total 27 19 46
*p<0.05, 2-sided Fisher’s exact test
To gain aetiological clues a cancer-related family
history in a private oncology practice cohort of 66
subsequent CLL patients has been evaluated.
Materials and methods
A cohort of 66 consecutive patients with CLL was
studied in a medical oncology practice (W.W.) from
1981 until 2005.
The diagnoses of CLL were made by standard clinical,
haematological and immunological criteria. The family
history was elicited with a German version of the NCI
medical history questionnaire for cancer aetiology [7].
The anamnestic data were verified as far as possible by
obtaining copies of medical and pathology reports. Every
pedigree was carefully examined for aetiological clues.
In addition familial clustering analyses was made by
comparing the proportion of specific tumours among all
diagnosed tumours in the first degree relatives (FDR) of
the probands with corresponding proportions of incidence
data of the years 1981 and 1982 in the population of
Geneva, Switzerland and of the years 1983-1987 in the
population of Basel, Switzerland [8, 9].
Results
CLL patients (probands)
The 66 probands were 44 male (median age: 67
years; range 39 years to 85 years) and 22 female
(median age: 65 years; range 38 years to 88 years).
The age distribution of the probands corresponds to
the age distribution of patients in the general
population (Kolmogoroff-Smirnoff-test).
47 (71%) CLL were typed immunologically: 46 had
B-CLL and 1 had T-CLL. 18 male patients (41%) and
5 female patients (23%) had multiple malignancies
(Table 1).
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First degree relatives (FDR)
46 (12%) of the 372 FDR had malignancies. There
was a significant excess of CLL, other leukaemias, and
of malignancies of uncertain origin, of oesophagus
and brain (Table 2).
In 5 families (8%) CLL occurred in relatives. Affected
were mother and sister in one family, fathers in two
families, mother and sister in one family each.
Discussion
CLL patients
The CLL patients frequently had multiple primary
cancers, confirming previous reports [10]. In our study
there is male dominance and CLL is associated with
malignancies of the skin, prostate, lung, urinary tract,
anus, meninges and bone marrow (myeloproliferative
diseases). The observed/expected ratio was 1.20 (95%
confidence interval: 1.15-1.26) in a population-based
US study [11].
Cancer prevention and early detection should be
continued in CLL patients because of their longevity and
high risk for second malignancies. These should be
treated as they would be in patients without CLL [12].
Families of CLL patients
CLL clusters in some families like any other disease
[13]. The transmission pattern suggests a dominant
model of heredity [14]. Inherited predisposition to CLL
is detectable as subclinical monoclonal B-lymphocyte
expansion [15].
Gains and losses in two regions of the X
chromosome, Xp11.2-p21 and Xq21-qter, appear more
common in familial CLL than in sporadic CLL [16].
Another candidate region is on chromosome 13 [17].
Predisposition genes should be searched. Serum
B-lymphocyte stimulator (BlyS) levels are elevated in
patients with familial B-CLL [18]. Elevated BLyS levels
correlate with the presence of a T at –871 in the BLyS
promoter [18].
In our study oesophageal and brain cancers were
overrepresented in male first degree relatives. There
were also 4 stomach cancers, not reaching statistical
significance. In Bulgaria stomach cancer was
particularly often diagnosed in families of CLL patients
[19]. In addition one of our CLL patients (woman, 
40-years-old at diagnosis) had a brother with duodenal
gastrointestinal stomach tumour (GIST) at age 36. The
frequent occurrence of upper GI malignancies in FDR
of CLL patients calls for targeted oesophago-gastro-
duodenoscopy screening studies.
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